Title of Invention

MONOPARAIMMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMA VIRUSES

Abstract The invention relates to monoparaimmunity inducers that are based on paraimmunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show the general symptoms of the disease. The invention also relates to a method for producing the inventive inducers and to their use as drugs for the regulatory optimization of the paraimmunizing activities for use in the prophylaxis and therapy of various human and animal dysfunctions.
Full Text MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT
MYXOMAVIRUSES
The invention relates to monoparamunity inducers based on paramunizing viruses or viral components, charac-terized in that the viruses or viral components are derived from an attenuated rabbit myxomavirus strain, to a method for producing the monoparamunity inducers and to the use thereof as medicaments.
The endogenous immune system of highly developed organisms, especially that of mammals and birds., includes an antigen-specific and an antigen-nonspecific part. Both parts of the immune system are linked together and moreover interact with one another. The antigen-specific mechanisms are responsible for building up immunity, and the antigen-nonspecific are responsible for building up paramunity. Paramunity refers to the state of a well regulated and optimally functioning nonspecific defense system linked to a rapidly developing, time-limited, increased protection from a large number of different pathogens, antigens and other noxae. The basis for the development of paramunity are, for historical and functional reasons, the nonselective and conditionally selective paraspecific defense mechanisms which are old from the phylogenetic viewpoint and are called primitive.
The paraspecific activities of the antigen-nonspecific immune system (also: "innate immune system") include nonselective protective elements such as, for example, foreign material-consuming organelles, and conditionally selective protective elements such as, for example, micro- and macrophages, natural killer cells, dendritic cells and soluble factors such as cytokines, which show pathogen-nonspecific or antigen-nonspecific reactions according to their origin.

- 2 -
Paraspecific activities are to be observed in the relevant organism immediately after antigen contact, whereas the effects of the antigen-specific immune system appear only after days or weeks.
In the more highly organized life forms, time is additionally gained thereby in order to build up specific defense systems against the noxae which it has not yet been possible to eliminate and have antigenic properties.
The benefits of paramunization i.e. the paraspecific activities of the immune system for prophylaxis and therapy in a patient have become increasingly clear since its development (Anton Mayr, "Paramunisierung: Empirie oder Wissenschaft", Biol. Med. edition 26(6): 256-261, 1997) . The paraspecific defenses make it possible for the organism to defend itself immediately on confrontation with a wide variety of foreign materials, infectious pathogens, toxins and transformed endogenous cells.
There are close interactions between the paraspecific and the specific .activities of the immune system, with the flow of information usually proceeding from the initially reacting paraspecific part to the specific part, with a later onset, of the immune system (e.g. with antigen mediation) . In the event of infections with particularly virulent pathogens, the paraspecific defenses of the organism are able in this way to cover the time until specific immunity develops (e.g. antibodies, immune cells).
The paraspecific immune defenses are a physiological process and can be defined as "primary control" in the confrontation with the environment. They are indispensable not only for lower organisms but in particular also for the more highly developed and highly developed vertebrates. Primary congenital

— 3 —
defects in this biological defense system lead to life-threatening situations. An example which may be mentioned is the "Chediak-Steinbrinck-Higashi syndrome" in humans, which is characterized by granulocyte deficits and dysfunctions of natural killer cells (NK cells) and in most cases leads to the death of the patient by completion of the 10th year of life.
The condition of paramunity is characterized by an increased rate of phagocytosis, an increased function of the spontaneous cell-mediated cytotoxicity (NK cells) and increased activity of other lymphoreticular cells. At the same time there is release of particular cytokines which have stimulating and/or inhibiting effects (e.g. via repressor mechanisms) both with the cellular elements and with one another. This closely linked and stepwise responding biological system of paramunity with its various acceptor, effector and target cells and the signal-transmitting cytokines is . moreover thoroughly connected to the hormonal and nervous systems. It thus represents an important constituent of the communication, interaction and regulation network.
Paramunity is induced by paramunization. By this is meant the pharmacological activation of the cellular elements of the paraspecific part of the immune system and the production, associated therewith, of cytokines, with the aim of eliminating dysfunctions, rapidly increasing the non-pathogen- and non-antigen-specific protection of an individual (optimal bioregulation), eliminating an immunosuppression or immunodeficiency which has arisen from the consequences of stress or otherwise (e.g. pharmacologically), repairing deficits and/or acting as regulator between the immune, hormonal and nervous systems. This means that certain nonspecific endogenous defense processes can be increased, supplemented or else depressed, depending on the type of paramunization and the responsiveness, such

- 4 –
as, for example, the health status of the patient.
Paramunity inducers are used for the pararaunization and must meet certain criteria of harmlessness and efficacy, thus differing from immunostimulants. The paramunity inducer per se is not comparable either to an antibody or to a chemical, an antibiotic, vitamin or hormone. On the contrary, it activates by a stepwise mechanism the paraspecific immune system, so that the latter sufficiently mobilizes cellular and humoral defense mechanisms. The paramunity inducer in this case has both regulating and repairing effects on the immune defenses. Concerning the mode of action of paramunity inducers, it is known that they are taken up by phagocytic cells (acceptor cells) which are thus activated and release mediators which in turn mobilize effector cells. The latter finally switch on the regulatory mechanisms of the paraspecific defenses.
Multiple paramunity inducers based on combinations of two more poxvirus components derived from different poxvirus strains with paramunizing properties are described in European patent EP 0 669 133 Bl.
The present invention is based on the paramunizing properties of attenuated myxomaviruses and/or their viral constituents.
Attenuation refers to the modification of the properties of an infectious pathogen which lead to weakening of the pathogen ("attenuate" = weaken, mitigate). Alterations in infectious pathogens frequently occur spontaneously in nature, it being possible for the timespans to extend over many centuries.
The ability of infectious pathogens to change in order to adapt to environmental changes can be utilized experimentally, and the timespan necessary for

- 5 -
attenuation can be drastically shortened for example by long-term passages in certain host systems. Attenuation has been utilized to date to obtain avirulent inoculation strains and harmless paramunity inducers.
Attenuation normally leads to loss of virulence and contagiousness, reduction in the immunizing properties and the host range, and to small changes in the pathogen genome with the occurrence of deletions, preferably in the terminal regions. There is usually parallel increase in the paramunizing activities of the modified pathogen.
In rare cases, an attenuation may, especially when an experimental attenuation by genetic manipulations is attempted, also lead to an increase in the virulence and contagiousness.
Myxomaviruses are the pathogens of myxomatosis, a contagious systemic viral disease of wild and domestic rabbits which progresses in cycles and is characterized by generalized, in some cases hemorrhagic subcutaneous edemas on the head and over the entire body, with preference for the anal region, the vulva and the tube, unlike any other infectious disease. Introduction of myxomatosis into a country previously free of the disease results in rapid and fatal progression. After the virus has become endemic, the character of the disease changes until the infections are clinically inapparent (Mayr . A. : Medizinische Mikrobiologie, Infections- und Seuchenlehre, 7th edition, Enke-Verlag, Stuttgart, 2002).
The disease is widespread among American cottontail rabbits of the genus Sylvilagus which occupy exclusively the New World. These wild rabbits form the only natural reservoir of the disease. The infection takes a mild form in them. By contrast, the disease has an almost 10 0% mortality in European wild and domestic

- 6 -
rabbits of the genus Oryctolagus, which are also naturalized in Australia, when the pathogen is introduced.
The natural host range of the myxomavirus (genus Leporipoxvirus) has narrow limits. In general, the virus replicates only in American cottontail rabbits and in European domestic and wild rabbits. However, a few infections in European wild hares have also been observed. Attempts at transmission to other species and to humans had negative results.
The present invention is based on the object of providing novel monoparamunity inducers for human medicine and veterinary medicine. A further object of the present invention is to provide a. method for producing such monoparamunity inducers. It is additionally an object of the present invention to provide pharmaceutical compositions for use as medicaments based on monoparamunity inducers.
Accordingly, the present invention relates to monoparamunity inducers based on paramunizing viruses or viral components, characterized in that the viruses or viral components are derived from an attenuated rabbit myxomavirus strain. The viral components preferably include paramunizing viral envelopes or aberrant forms of viral envelopes of an attenuated myxomavirus strain. Preferred strains having the paramunizing properties of the invention are the strains M-2, M-7, Lausanne, Aust/Uriarra/Verg-86/l. The strains M-7, Lausanne, Aust/Uriarra/Verg-86/l are also suitable for producing live vaccines because they have undergone only partial attenuation of their virulence in order to have an adequate immunizing effect.
A monoparamunity inducer based on the myxomavirus strain M-2 is particularly preferred. An attenuated myxomavirus strain produced by the method of the

- 7 -
invention described hereinafter has been deposited at the depository of the Public Health Laboratory Service (PHLS), Centre for Applied Microbiology & Research, European Collection of Animals "Cell Cultures (ECACC), Salisbury, Wiltshire, United Kingdom with the deposit number 03121801.
The invention further relates to a method for producing monoparamunity inducers based on an attenuated rabbit myxotnavirus strain. For this purpose, initially myxomaviruses are isolated from infected tissue of a rabbit typically suffering from a generalized myxomatosis. The virus is subsequently adapted to a permissive cell system, i.e. to a cell material which permits replication of the virus, such as, for example, cell cultures, incubated chicken eggs or else experimental animals. It is possible in particular to use cells of the natural host or of a species closely related to the host for the adaptation. Examples of suitable permissive cell systems for myxomaviruses are chick embryo fibroblasts (CEF) as well as cell cultures produced from rabbit kidneys or testes.
It is preferred according to the invention to adapt the isolated myxomavirus to the chorioallantoic membrane (CAM) of incubated chicken eggs over one or more passages, preferably over 2 to 6 passages, and particularly preferably over 3 passages. For this adaptation, the isolated viruses are inoculated onto the CAM and replicated by passaging on the CAM.
The myxomaviruses are preferably initially isolated from infected tissue by replication in a permissive cell system. For this purpose it is possible to inoculate a permissive cell system for example with infected tissue homogenate obtained by disruption. Subsequently, the viruses obtained by the initial replication are either adapted further to the same permissive cell system, which was already used for the

- 8 -
isolation, or another, fuarther permissive cell system is used. Adaptation of the virus to the same permissive cell system type which is also used for the isolation is preferred. Thus, preferably myxomaviruses from infected tissue are isolated by replication in a permissive cell system and subsequently adapted to the permissive cell system by further passages. Initial culturing and isolation of the myxomaviruses by replication on the CAM of incubated chicken eggs and subsequent adaptation of the virus on the CAM over further passages, preferably over a further 2 passages, is particularly preferred. However, it is also possible alternatively to use the allanotoic fluid of incubated chicken eggs for the culturing and/or adaptation.
The actual attenuation then takes place by long-term passages on one or more permissive cell cultures, until an attenuation or the desired degree of attenuation of the virus is reached. It is possible for this purpose firstly to test various permissive cell systems for replication of the virus and subsequently to select one or more cell systems in which the highest infectious titers are reached for further passages. Both primary and secondary cell cultures as well as permanent and continuous cell lines are suitable for attenuation by long-term passages. Thus, attenuation can take place by replication in primary or secondary chick embryo fibroblast (CEF) cultures or in cultures of permanent CEF cells.
Preferred according to the invention for attenuation of the .myxomavirus is to passage or replicate the virus in a permanent cell culture, in particular a Vero cell culture, preferably over 80 to 150 passages and particularly preferably over 12 0 passages. Alternatively or additionally, the virus is passaged according to the invention on a binary permanent cell line, in which case AVIVER cells are preferably used. These cells or cell culture has been obtained by cell

- 9 -
fusion between chick embryo fibroblasts (CEF) and Vero monkey kidney cells. For the myxomavirus attenuation of the invention, the isolated and adapted viruses are preferably passaged in a first step in Vero cell cultures, the viruses are then transferred into a binary AVIVER cell culture and replicated therein preferably over 10 to 50 passages, in particular over 2 0 to 3 0 passages, and particularly preferably over 25 passages.
The attenuated myxomavirus can then be additionally replicated over further attenuation passages. Further replication of the viruses preferably takes place over further passages in Vero monkey kidney cells, in particular over 100 to 200 passages.
A particularly preferred further method step is additional inactivation of the attenuated myxomavirus. Inactivation can take place by chemical treatment, irradiation, the action of heat or pH, in particular by a chemical treatment with beta-propiolactone. Treatment of the attenuated myxomaviruses with beta-propiolactone increases the paraspecific activities further, while the immunizing properties which are still present where appropriate after the attenuation are lost.
A particularly preferred embodiment of the method of the invention includes the following steps:
isolation of myxomaviruses from the infected tissue of a rabbit suffering typically from generalized myxomatosis by replication on the chorioallantoic membrane (CAM) of incubated chicken eggs and subsequent adaptation of the virus to the CAM over a further 2 passages;
attenuation of the isolated viruses by passaging in Vero cell cultures, preferably over 12 0 passages;
transfer of the viruses into a binary AVIVER cell culture, where the AVIVER cells have been obtained

- 10 -
by cell fusion between chick embryo fibroblasts (CEF)
and Vero monkey kidney cells, and attenuation of the
virus in this cell culture over 10 to 50, preferably
25, passages,
subsequent transfer of the virus back onto Vero monkey kidney cells and replication of the viruses by further attenuation passages in the Vero cells, preferably over about 150 passages; and optionally
inactivation of the attenuated myxomaviruses by treatment with beta-propiolactone, this treatment increasing the paraspecific activities, while the immunizing properties still present after the attenuation are lost.
Attenuation by long-term passaging is usually concluded by 3 to 5 plaque end dilutions. After various clones have been obtained and tested, the clones selected for further replication are those with which the highest infectious titers are achieved and with which a high paramunizing activity - e.g. in the VSV challenge test in the baby mouse - are detected. This procedure is intended to ensure in particular that genetically uniform virus material is provided for further use.
The term "attenuation" as used in connection with this invention refers to the experimental modification of the originally virulent myxomavirus into the modified form, with a simultaneous increase in the paramunizing properties. The attenuation is detectable through one or more of the following properties:
reduction or weakening or loss of virulence for European domestic and wild rabbits (genus Oryctolagus caniculus csp.),
weakening or loss of contagiousness, restriction of the host range in cell cultures, alteration of the immunizing properties acquisition of paramunizing, short-term protective activities.

- 11 -
An attenuation may lead to deletions in the terminal region of the myxomavirus genome. An increasing degree of attenuation is frequently observed to be associated with an increasing number of deletions in the viral genome.
The degree of attenuation can be checked and monitored during the passages by appropriate suitable activity tests as known in the art (cf., for example, US 6,805,870, column 12, and the further references cited therein) and by cloning.
The present invention further relates to attenuated myxomaviruses obtainable by the method of the invention, pharmaceutical compositions including the attenuated myxomavirus or the myxomavirus mono-paramunity inducer of the invention, and to the use of the myxomavirus monoparamunity inducers for activating the paraspecific immune system in a mammal and to the use of the attenuated virus for producing a corresponding medicament.
Because of the surprising paramunizing properties, the myxomavirus monoparamunity inducers of the invention are suitable for the treatment and/or for the prophylaxis of immune system dysfunctions, immuno-suppression, immunodeficiency disorders, dysfunctions of homeostasis between the hormonal, circulatory, metabolic and nervous systems, threatened neonatal infection, neoplastic diseases, viral diseases, bacterial diseases, therapy-resistant infectious factor diseases, viral and bacterial mixed infections, chronic manifestations of infectious processes, liver disorders of various etiologies, chronic skin disorders, herpetic diseases, chronic hepatitides, influenzal infections, endotoxin damage.
The monoparamunity inducers of the invention are generally harmless to the environment and effective in

- 12 -
the sense of paramunization for mammals such as, for example, humans, horses, dogs, cats, pigs, for birds and also for reptiles such as, for example, lizards, snakes, chelonians. They are therefore particularly suitable for use in human and veterinary medicine.
In addition, the monoparamunity inducers of the invention display a very good paramunizing activity with high potency. They can be produced by the method of the invention in a suitable manner and are safe for use in the medical sector. The attenuation of the myxomaviruses reduces the immunizing properties of the myxomaviruses while the paraspecific activities increase. The monoparamunity inducers of the invention therefore have paramunizing, but no immunizing, properties, making multiple and continuous use possible. These paramunizing properties of the rabbit myxomavirus and of its paramunizing viral components are surprising and were not predictable.
The term "paramunization" as used in connection with this invention refers to the pharmacological activation of the cellular elements of the paraspecific immune system and the production or release, associated therewith, of cytokines with the aim of eliminating dysfunctions, rapidly increasing the non-pathogen- and non-antigen-specific protection of an individual, and having a regulatory effect between the immune, hormonal, nervous and vascular systems. Paramunization leads to the protected state of paramunity.
The term "paramunity" as used in connection with this invention refers to the actively acquired state of an optimally regulated and functioning paraspecific defense system, associated with a rapidly developing, time-limited protection from a large number of pathogens, antigens and other noxae. The phagocytosis rate, the function of the NK cells (natural killer cells) and the activity of other lymphoreticular cells

- 13 -
(e.g. dendritic cells) are raised to the physiological optimum.
The term "paramunity inducer" as used in connection with this invention refers to a pyrogen-free, nontoxic medicament which is intended to be used in humans and animals to generate and regulate endogenous defense and protective mechanisms in the sense of paramunization.
The term "myxomavirus monoparamunity inducer" as used in connection with this invention refers to a medicament which is based on attenuated rabbit myxomaviruses or an attenuated myxomavirus strain, including the paramunizing viral components and the constituents thereof which produce the state of paramunity in an organism, preferably in a mammal (e.g. human).
The term "myxomavirus" as used in connection with this invention refers to the species of the myxomatosis virus of the genus Leporipoxvirus. The myxomavirus belongs to the subfamily of Chordopoxviridiae and to the family of Poxviridae (poxviruses).
The term "paramunizing viral components" as used in connection with this invention includes a large number of viral structures derived from a myxomavirus having paramunizing properties, for example viable or inactivated freshly isolated myxomaviruses, viable or inactivated recombinant myxomaviruses derived from freshly isolated myxomaviruses, viral envelopes, the removed envelopes and cleavage products and aberrant forms of these envelopes, individual native or recombinant polypeptides or proteins, in particular membrane and surface receptors which occur in freshly isolated myxomaviruses or are recombinantly expressed by a genetically modified myxomavirus or a part of its genetic information.

- 14 -
Tables 1 to 4 summarize the clinical results with the myxomavirus monoparamunity inducer PIND-MYXO based on the attenuated myxomatosis cell culture virus, strain M-2, in humans.
Table 1 shows the clinical results on prophylactic use of the myxomavirus monoparamunity inducer PIND-MYXO in humans.
Table 2 shows the clinical results on therapeutic use of the myxomavirus monoparamunity inducer PIND-MYXO in humans.
Table 3 shows the effect of paramunization with myxomavirus monoparamunity inducer (PIND-MYXO) in patients with low immune parameters (7 days after PIND-MYXO administration).
Table 4 shows the effect of paramunization with myxomavirus monoparamunity inducer (PIND-MYXO) in patients with elevated immune parameters (7 days after PIND-MYXO administration).
The invention is based on the surprising finding that attenuated rabbit myxomaviruses or their paramunizing constituents are able to induce very good paramunizing properties in a recipient organism which lead to the protected state of paramunity. The basis for this invention was the first successful attenuation of rabbit myxomaviruses in cell cultures.
The monoparamunity inducers of the invention are preferably based on lyophilized, attenuated and inactivated rabbit myxomaviruses or their paramunizing . viral components. The attenuated myxomaviruses or their viral components of the invention are preferably derived from one myxomavirus strain or a plurality of different attenuated myxomavirus strains. It is preferred in this connection for the monoparamunity

- 15 -
inducers of the invention to include combinations of one or more myxomavirus strains or their paramunizing viral components.
The paramunizing properties induced in a mammal such as, for example, in humans through administration of myxomavirus monoparamunity inducer are particularly beneficial for eliminating dysfunctions, for increasing the non-antigen-specific protection of an individual, for eliminating an immunosuppression or immunodeficiency which has arisen from the consequences of stress or in other .ways (e.g. pharmacological) and in order to have regulatory effects between the immune, hormonal and vascular systems.
The. invention is further based on successful attenuation of a myxomavirus strain by passaging through cell cultures, with the virulent and/or immunizing properties, of the myxomavirus strain being reduced or lost. Additional inactivation of the myxomaviruses can moreover take place by irradiation, the action of heat or pH, or, particularly preferably, by a chemical treatment with beta-propiolactone. The monoparamunity inducers are based on attenuated, lyophilized myxomaviruses, with individual viral components of a myxomavirus which are suitable for inducing paramunizing activities in an organism also being encompassed by the invention.
It is intended below to describe one embodiment of the production method of the invention for monoparamunity inducers based on an isolated and attenuated rabbit myxomavirus strain via cell culture passaging. The production method is moreover not restricted to this preferred strain, but can be applied in the same way to other rabbit myxomavirus strains. Also encompassed by the present invention are recombinant forms of a myxomavirus strain which have been produced by genetic modification. Preference is given in this connection to

- 16 -
recombinant myxomavirus strains in which one or more segments in the genome which code for cytokine receptors has been modified by a modification in the form of an addition, substitution or deletion, with the receptor properties of the cytokine receptor being lost through the modification. These are preferably the gene segments which code for the receptors for interferons (IFN), interleukins (IL) and tumor necrosis factors (TFN), in particular for IFN-a-R, IFNy-R, TNF-R, IL-l-R, IL-2-R, IL-6-R and IL-12-R.
In addition, the numerical values stated herein concerning the incubation time or the number of passages over cell cultures are not intended to be regarded as restrictive. Slight modifications of these parameters and modifications evident to the skilled worker and also leading to a preparation of attenuated myxomaviruses are equally encompassed by this invention.
A preferred embodiment of the present invention relates to the successful attenuation of the myxomavirus strain M-2. The myxomavirus strain M-2 was isolated from European wild rabbits suffering from myxomatosis (Herrlich A., Mayr A. and Munz E.: "Die Pocken", 2nd edition, Georg Thieme Verlag, Stuttgart, 1967) . The altered skin cells obtained from the subcutaneous tissue of the diseased rabbit are, after disruption, inoculated onto the chorioallantoic membrane (CAM) of chicken eggs which have been incubated preferably for 10-12 days. The myxomaviruses are further replicated and adapted over 2 to 6 passages, preferably over 3 passages, on the chorioallantoic membrane (CAM passages; for method, see Herrlich A., Mayr A. and Munz E.: "Die Pocken", 2nd edition, Georg Thieme Verlag, Stuttgart, 1967) . The 2nd to 6th passage, preferably the third CAM passage, serves as starting material for the further attenuation of the myxomavirus in cell cultures. The attenuation takes place after

- 17 -
adaptation of the viruses in the chorioallantoic membrane (evident from typical foci on the chorioallantoic membrane) in 3 stages. In stage 1, 8 0 to 150, preferably 120, continuous so-called end-dilution passages take place in Vero cells (Vero cells, ATCC CCL-81) . The virulence of the myxomavirus which has undergone these passages is weakened.
In a 2nd stage after the 80th to 150th passage, preferably after the 12 0th passage, in Vero cells, the viral suspension is transferred to so-called AVIVER cells and continued over 10 to 50 passages, preferably over 20 to 30, in particular over 25, passages. AVIVER cells are obtained by cell fusion between chick embryo fibroblasts (CEF) and Vero cells and are referred to as binary permanent cell culture.
The last passage over AVIVER cells, preferably the 25th passage, is transferred back to Vero cells and is continued in the 3rd stage of attenuation for a further 100 to 200 passages, preferably about 157 passages, in Vero cells. In this way, the myxomavirus is replicated over a total of more than 300 cell culture passages. After the 3rd stage of replication of the myxomavirus in cell cultures, the myxomavirus is sufficiently attenuated.
The Vero cell cultures and the AVIVER cells are preferably cultured using a completely synthetic medium, particularly preferably the MEM medium (minimal essential medium) plus 5 to 20%, preferably 10%, BMS (serum substitute medium) and 5 to 20, preferably 10%, lactalalmin hydrolysate. The virus medium used after exchange with the culture medium is preferably MEM medium with 5 to 2 0%, preferably with 10%, lactalalbumin hydrolysate, without BMS or without fetal calf serum and without antibiotics. All the production methods are preferably carried out at pH values of 7.0 to 8.0, preferably at a pH of 7.25. Virus harvests with

- 18 -
titer from 105.0 to 107.5, preferably of at least 106.5 TCID50/ml (TCID50 = 50% tissue culture infectious dose) are preferably suitable as starting material for producing the monoparamunity inducer PIND-MYXO of the invention.
Replication of the myxomavirus in Vero cells leads to a typical cytopathic effect (cpE) which is ultimately characterized by a destruction of the infected cells (lysis) . Inoculation with a dose of about 10 MOI (multiplicity of infection) results after a short rounding phase (1-2 days) in reticulated cell structures for about 3 days and in lysis of the cells after about 5 days. The 301st passage in Vero cells had an infectious titer of about 106.5 TCID50/ml.
The attenuated myxomavirus is inactivated by a chemical treatment with beta-propiolactone at a concentration of 0.01-1% beta-propiolactone, preferably at a concentration of 0.05% beta-propiolactone. This inactivation leads to a complete loss of the immunizing properties which are still present where appropriate, while the paraspecific activities are not only retained but in fact significantly increase.
For further processing of the attenuated and inactivated myxomaviruses to a myxomavirus monoparamunity inducer (PIND-MYXO), the virus starting material used for the virus inactivation should have a viral titer of about 105.0 to 107.0, preferably of at least 106.5, TCID50/ml.
Purification preferably takes place by centrifugation at low revolutions (e.g. 1000 rpm). After the centrifugation, 0.5-10% succinylated gelatin (e.g. polygeline, e.g. from Hausmann, St Gallen/Switzerland), preferably 5% succinylated gelatin, is added. The resulting mixture can subsequently be lyophilized in 1.5 ml portions in appropriate sterile glass vials or

- 19 -
ampoules and, if required, dissolved in distilled water. A volume of 0.5-2 ml, preferably of 1.0 ml of the lyophilisate dissolved in distilled water corresponds to an inoculation dose for humans on intramuscular administration (see also Mayr A. and Mayr B.: "Von der Empirie zur Wissenschaft", Tierarztl. Umschau, edition 56: 583-587, 2002).
The attenuation can be detected clinically through the loss of virulence for European domestic and wild rabbits (genus Oryctolagus caniculus csp.), through a loss of contagiousness, through a virtually complete restriction of the host range in cell cultures and through the alteration in the immunizing properties.
The lyophilized product can be stored at temperatures of, preferably, about +4°C or at lower temperatures, preferably about -60°C, with stability for an unlimited time.
It was demonstrated by gene technology investigations
of the prepared attenuated myxomaviruses that multiple
deletions had occurred in the myxomavirus genome. In
the case of the initial strain M-2,, the myxomavirus
genome consists of a single linear deoxyribonucleic
acid (DNA) with a total length of about 160 kilobases
(kb) , which codes. for several hundred proteins
(Herrlich A., Mayr A. and MunzE.: "Die Pocken", 2nd
edition, Georg Thieme Verlag, Stuttgart, 1967) . The
sequences of the terminally located inverted repeats
(terminal inverted repeats, TIR) are situated at about
11 kb of the genome segment (McFadden, G. and
Graham K.: "Modulation of cytokine networks by pox
virus", Virology, edition 5: 421-429, 1994).
Thus, it has been found that the attenuation of the
myxomaviruses over continuous Vero cell passages has
led to a loss of . the coding gene segments for the
receptors for interferon a and y (IFN a, IFNy) , for

- 20 -
tumor necrosis factor (TNF) and for the interleukins (IL) 1, 2, 6 and 12. It is of interest that these cytokines belong to the paraspecific defense factors of the nonspecific immune system. The cytokines are neutralized by binding to the corresponding viral receptors, so that the virus is able to replicate unimpeded. The deletions of gene segments which code for the abovementioned cytokine receptors relate mainly to the terminal regions of the DNA. However, it was additionally possible to detect deletions which occured during the AVIVER cell passages in the conserved part of the DNA. These deletions relate to two genes which code for an immune epitope and virulence gene. Such genetic modifications are presumably one of the reasons for the decrease in the immunizing, i.e. antigen-specific, activities and the simultaneous increase in the paraspecific activities of the attenuated myxomavirus.
The immunizing epitopes and the paraspecific and nonspecific epitopes are in competition. A decrease in the first-mentioned peptides or proteins therefore leads to an increase in the effect of the paraspecific activities. Residues of. immunizing and virulence-increasing proteins are eliminated in the preparation of monoparamunity inducers by the method described above for inactivating the attenuated myxomaviruses.
The monoparamunity inducer of the invention, also called PIND-MYXO, is based on the use of attenuated myxomaviruses or the paramunizing constituents thereof and is suitable on the basis of its paramunizing properties for the following prophylactic or therapeutic indications in a patient:
- infectious factor diseases and mixed infections, chronic manifestations of infectious processes, refractory recurrent infections and chemotherapy-resistant bacterial and viral infections

- 21 -
- weakened defenses and dysregulations in the defense
system of an organism
- threatened neonatal infection
- adjuvant therapy for certain neoplastic diseases,
e.g. prevention of metastasis, reduction of side
effects due to chemo- and radiotherapy
- regulation of homeostasis between the hormonal,
circulatory, metabolic and nervous systems.
The paramunity inducers of the invention can be administered parenterally or locally to mammals, including humans, birds and reptiles. Local administration of paramunity inducers specifically stimulates the paraspecific defense mechanisms in the mucous membranes and in the skin. However, there is also a certain systemic effect. By contrast, parenterally applied paramunizations scarcely influence the local defense mechanisms in the skin and mucous membrane, preferably having a systemic effect.
Side effects do not occur even with numerous parenteral administrations carried out continuously in humans and animals. The indications for the use of PIND-MYXO are the same for animals and for humans. At the same time, in problem operations, specifically in the management of horses, pigs, dogs and cats, pararrvunization of neonates immediately on the day of birth and preferably on the first and possibly also the second day after birth is advisable. The single dose is about 0.5 to 5 ml of the dissolved lyophilisate, in horses and pigs the single dose is preferably 2 ml and in dogs and cats is preferably 0.5 ml on parenteral administration. It is advisable according to the invention to administer PIND-MYXO parenterally one day before and/or at the same time as specific protective inoculations in order

- 22 -
to avoid secondary reactions and to assist the immunization on administration of vaccines.
One embodiment of the invention relates to the production of a pharmaceutical composition for local administration to induce paramunity in the skin and mucous membranes. The pharmaceutical composition preferably relates to a buccal or suckable tablet based on constituents of an attenuated and inactivated myxoma cell culture, virus. The buccal tablets of the invention are preferably produced with addition of sorbitol, polyethylene glycol 6.00, potassium hydrogenphosphate, Tyrospirol tablet essence, Kollidon 25 and magnesium stearate. PIND-MYXO can, however, also be administered nasally, rectally or vaginally with suitable carriers.
The following examples are preferred embodiments of the invention and serve to explain the subject matter of the invention further.
Example 1
The myxomavirus from the edematous subcutis of a
European wild rabbit (genus Oryctolagus) suffering in a
typical manner from myxomatosis was isolated as
starting material for producing the monoparamunity
inducer PIND-MYXO of the invention by culturing on the
chorioallantoic membrane (CAM) of chicken eggs (Valo
eggs) incubated for 10 days and was adapted three times
by the method of Herrlich et al. in passages on the CAM
(Herrlich A., Mayr A. and Munz E.: "Die Pocken", 2nd
edition, Georg Thieme Verlag, Stuttgart, 1967) . The
third CAM passage was adapted in a 1st stage on Vero
cells over 120 passages (ATCC CCL-81, WHO, American
Type Culture Collection), replicated in a 2nd stage by
24 intermediate passages in AVIVER cell cultures, and
cultured further in the 3rd phase in Vero cells. In
total, about 3 00 passages aimed at attenuation were
carried out. After these continuous end-dilution

- 23 -
passages, the originally virulent myxomavirus was attenuated.
The attenuated myxomavirus is replicated in Vero cells. The Vero cell cultures are cultured using a completely synthetic medium consisting of MEM (minimal essential medium) plus 10% BMS (serum substitute medium) and 10% lactalbumin hydrolysate. The virus medium used after exchange with the culture medium is only MEM with 10% lactalbumin hydrolysate without BMS or without fetal calf serum and without antibiotics. All production methods are carried out at pH values above 7.25. Viral harvests with titers above 106.5 TCID50/ml serve as starting material for producing the monoparamunity inducer PIND-MYXO of the invention. Inactivation of the viral harvests with 0.05% beta-propiolactone and low-speed centrifugation are followed by addition of 5% of succinylated gelatin (polygeline) to the virus material before lyophilization.
The lyophilized product is stable at room temperatures and at temperatures of about 4°C to -80°C and can be kept without time restriction1 preferably at about 4°C or else about -60°C. A volume of 1 ml of the lyophilisate dissolved in sterile distilled water corresponds to an inoculation dose. Deep intramuscular or local administration takes place (see examples 3, 4 and 5).
Example 2
The PIND-MYXO inducer of the invention is administered in an analogous manner to the description in example 1 in dry form (lyophilisate not dissolved) locally onto the mucous membranes of the upper respiratory tract, preferably nasally, three times a day for prophylaxis or therapy (1 ml per application) of multifactorial infections (e.g. influenzal infections).

- 24 -Example 3
The PIND-MYXO inducer in liquid form produced as in example 1 is in an analogous manner rubbed in cutaneously to improve the perfusion of the skin, to speed up the healing of wounds and to treat varicose veins and chronic venous - insufficiency (leg ulcer) in humans. The lyophilisate can for this purpose be taken up for example in greasy cream (e.g. Bepanthen, Linola fat), in which case the pH should be slightly alkaline. This preparation should be prepared fresh for each use. Administration is carried out several times a day by manual rubbing into the undamaged skin. Open wounds can be treated by dropwise application of the freshly dissolved product onto the wound regions. The treatment should take place, each day until healed.
Example 4
The monoparamunity inducer PIND-MYXO produced as in example 1 is analogously administered parenterally to prevent secondary reactions and to improve the result of inoculation one day before and simultaneously with a protective inoculation with conventional specific vaccines.
Example 5
The monoparamunity inducer PIND-MYXO produced as. in example 1 is processed analogously to buccal or suckable tablets. The production and use of the suckable tablets for local paramunization of the mucous membranes of the ear, nose, throat and mouth is novel and a constituent of the invention. Via the activated mucous membranes of the mouth there is not only a homing effect (migration of defense cells into mucous membranes of other organ systems), but also a partial parenteral paramunization. The following production method has,proved suitable for the production of buccal

- 25 -
and suckable tablets:
For the lyophilization, 5% Kollidon 25 (polyvinyl-pyrrolidone) is added instead of gelatin to the liquid inducer material. Urea, sorbitol, polyethylene glycol 6000 and magnesium stearate are required to produce the finished tablet. A recommended formula for a tablet with a weight of 500.5 mg in weight is:
PIND-MYXO lyophilisate 65 mg
Urea 50 mg
Sorbitol 2 67 mg
Polyethylene glycol 6000 118 mg
Magnesium stearate 0.5 mg
Tablet weight 500.5 mg
The patient should take 4-6 tablets at regular intervals each day to achieve an optimal paramunization.
The following formula of a pharmaceutical composition has proved suitable for producing buccal tablets:
PIND-MYXO lyophilisate 155 mg
Sorbitol 3 60. mg
Polyethylene glycol 6000 3 00 mg
Potassium dihydrogenphosphate (KH2PO4) , anhydrous 2 mg
Disodium hydrogenphosphate (Na2HPO4) , anhydrous 8 mg
Tyrospirol essence tablets 0.8 mg
Magnesium stearate 2 0 mg
Tablet weight 805.8 mg
The tablets slowly dissolve in the patient's mouth and can be swallowed after dissolving.
The clinical test results with the monoparamunity inducer of the invention, based on the lyophilisate of

- 26 -
the myxomavirus strain M-2, which are compiled i tables 1 to 4 demonstrate the very good paramunizir activities of myxomavirus lyophilisates in humans These data are equally applicable to other mammals e well as birds and reptiles.

- 27 -
Table 1:
Clinical results with a monoparamunity inducer from attenuated myxoma cell culture virus in humans
- prophylactic uses -(lyophilized inducer 1 OP (1 ml) intramuscular)

Indications Suitable administration methods
Periods of high infection
pressure 2 injections before the stress
Stress at an interval of 24 hours
Travel, examinations and
similar stresses
before or at the same time as
protective inoculations
Chemotherapy, irradiation
(reduction or prevention of 1 injection each day or every
secondary reactions) 2nd day until the treatment is
Operations complete or until recovery
(improvement in wound healing)
Maintenance of optimal
defenses and hemodynamics
1-2 injections per month at an
Prophylaxis of cancer and interval of 24 hours
hepatitides
Improvement in wellbeing


- 28 -
Table 2:
Clinical results with a monoparamunity inducer from attenuated myxoma cell culture virus in humans
- therapeutic uses -(lyophilized inducer 1 OP (1 ml) intramuscular)

Indications Suitable administration methods
1 injection per day for 3-5
Herpetic diseases days or until the symptoms
(zoster, infectious disappear; then one injection
mononucleosis, Herpes simplex, every 2nd or 3rd day until
etc.) complete recovery
Chronic hepatitides a "course" each month:
3 injections at intervals each
of 24 hours
Influenzal infections 1 administration per day until
viral and bacterial mixed the symptoms disappear, then 1
infections (in combination with injection every 2nd day until
antibiotics or chemotherapy) complete recovery
Immunodeficiencies and 1. intensive treatment for 5-10
dysregulation of the defense days:
systems (e.g. during or after 1 injection per day
chemotherapy) 2. then 2 injections per week
at an interval of 24 hours
(treatment over a longer period
possible)
Endotoxin damage 1 injection a day for 7 days or
until recovery


- 29 -
Table 3:
Effect of paramunization with myxoma inducer (PIND-MYXO)
in patients with low immune parameters (7 days after
PIND-MYXO administration)

Patient Patients' data Parameter Day 0 Day 7
Diagnosis/Therapy (normal range) *
A.S.
female, Immunosuppression leukocytes 4000 9400
52 years (4000-10000/µ1)
D.B. Ulcerative colitis lymphocytes 620 1360
female, cortisone therapy (900-3000/µ1)
54 years CD4 cells 400 920
(500-1800/µ1)
CD8 cells 80 210
(100-1000/µl)
U.S. Immunological leukocytes 3800 7400
male, impairment (4000-10000/µl)
3 8 years
S.C. Metastatic leukocytes 3800 9900
male, prostate carcinoma (4000-10000/µl)
43 years radiotherapy
B.M. Susceptibility to cytotoxic cells 0 248
female, infections (30-360/µl)
5 6 years


- 30 -
Table 4:
Affect of paramunization with Myxoma inducer (PIND-MYXO) in patients with elevated immune parameters (7 days after
PIND-MYXO administration)

Patient Diagnosis/Therapy Parameter (normal range) Day 0 Day 7
G.P., female,5 9 years Cervical, breast carcinoma, susceptibility to infections leukocytes (4000-10000/µl) granulocytes (2400-6400/µl) 12600 8420 8600 5930
C.H. female, 51 years Psychosomatic syndrome, obesity leukocytes (4000-10000/µ1) granulocytes (2400-6400/µl) 12700 9270 6000 4760

31
International patent application PCT/EP2005/000582 Our ref: BN 55 PCT
October 14, 2005
I/WE CLAIM:
1. A method for producing an attenuated rabbit myxomavirus strain comprising the steps of:
isolation of myxomaviruses from infected tissue of a rabbit typically suffering from generalized myxomatosis;
adaptation of the virus to a permissive cell system;
passaging of the isolated viruses in a Vero- and binary cell culture until attenuation of the virus is achieved.
2. The method according to claim 1, wherein the isolated viruses are inoculated onto the chorioallantoic membrane (CAM) of incubated chicken eggs for the adaptation.
3. The method according to claim 2, where the virus is replicated over 2 to 6 passages, preferably over 3 passages, on the CAM.
4. The method according to any one of claims 1 to 3, wherein the myxomaviruses present in the infected tissue are isolated by replication in a permissive cell system.
5. The method according to claim 4, characterized in that the virus is isolated by culturing on the chorioallantoic membrane (CAM) of incubated chicken eggs.
6. The method according to claim 5, characterized in that the virus is subsequently adapted to the CAM over further passages, preferably over 2 further passages.
7. The method according to any one of claims 1 to 6, characterized in that the attenuation of the myxomaviruses takes place over 80 to 150 passages, preferably over 120 passages, in Vero cell cultures.
8. The method according to any one of claims 1 to 7, wherein the virus is passaged in an AVIVER cell culture.
9. The method according to claim 8, characterized in that the passaging takes place over 10 to 50 passages, preferably over 25 passages.
10. The method according to any one of claims 1 to 9, wherein the attenuated myxomaviruses are additionally replicated over further attenuation passages.
11. The method according to claim 10, wherein the replication takes place in Vero monkey kidney cells.
12. The method according to claim 11, characterized in that the further growth takes place in Vero cells over 100 to 200 passages.
13. The method according to any one of claims 10 to 12, characterized in that the viral harvests of the cell culture have an infectious titer of from 105 to 1075, preferably of at least 1065, TCID50/ml.
14. The method according to any one of claims 1 to 13, wherein the attenuated myxomaviruses are additionally inactivated, preferably with beta-propiolactone.
15. The method according to claim 14, characterized in that the concentration of beta-propiolactone is 0.01-1%, preferably 0.05%.
16. The method according to any one of claims 1 to 15, comprising the steps of
isolation of myxomaviruses from the infected tissue of the rabbit suffering from myxomatosis by replication on the CAM of incubated chicken eggs and subsequent
adaptation of the isolated myxomavirus to the CAM over a further 2 passages
attenuation of the isolated viruses by
passaging in Vero cell cultures, preferably over 120 passages,
transfer of the viruses into the binary AVIVER cell culture with further attenuation of the virus, preferably over 24 intermediate passages, in this cell culture,
subsequent transfer of the virus back onto Vero monkey kidney cells, and
replication of the attenuated myxomaviruses by further attenuation passages in the Vero cells, preferably over about 150 passages.
17. An attenuated myxomavirus or a component thereof obtained by the method according to any one of claims 1 to 16.
18. An attenuated myxomavirus or a component thereof for use as paramunizing agent.
19. An isolated, attenuated myxomavirus, wherein the myxomavirus has lost the receptor properties of one or more myxomavirus interferon receptor, one or more myxomavirus tumor necrosis factor receptor, and one or more myxomavirus interleukin receptor.
20. A pharmaceutical composition including an attenuated myxomavirus or a component thereof as paramunizing agent and a pharmaceutically acceptable carrier.
21. The attenuated myxomavirus or the component thereof according to claim 17 or 18, the myxomavirus according to claim 19, and/or the pharmaceutical composition according to claim 20, characterized in that the myxomavirus is genetically modified.
22. The attenuated myxomavirus or the component thereof, the attenuated myxomavirus and/or the pharmaceutical composition according to claim 21, characterized in that the attenuated myxomavirus strain has a modification in the form of an addition, substitution or deletion in one or more gene segments coding for the production of cytokine receptors, with the receptor properties of the cytokine receptor being lost through the modification.
23. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to claim 22, characterized in that the cytokine receptors are selected from the group of receptors for interferons (IFN), interleukins (IL) and tumor necrosis factor (TNF).
24. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to claim 22 to 23, characterized in that the cytokine receptors are selected from the group of receptors for IFNa-R, IFN?-R. TNF-R, IL-1-R, IL-2-R, IL-6-R and IL-12-R.
25. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 24, characterized in that the viral components include viral envelopes or aberrant forms of viral envelopes of an attenuated myxomavirus strain.
26. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 25, characterized in that the myxomavirus strain is selected from the group consisting of M2, M7, Lausanne, Aust/Uriarra/Verg-86/1.
27. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 26. characterized in that the myxomavirus strain is deposited at the European Collection of Cell Cultures (ECACC) with the deposit number 03121801.
28. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 27, characterized in that the myxomavirus strain has been attenuated in cell cultures.
29. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to claim 28, characterized in that the cell cultures comprise Vero monkey kidney cells and/or AVIVER cells.
30. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 29, characterized in that the attenuated myxomaviruses are inactivated, preferably with beta-propiolactone.
31. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to claim 30, characterized in that the concentration of beta-propiolactone is 0.01-1%, preferably 0.05%.
32. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 31, characterized in that the myxomaviruses have been lyophilized.
33. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 32 for activating the paraspecific immune system in humans and animals.
34. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 33 for the parenteral treatment and/or for the prophylaxis of dysfunctions of the immune system, immunosuppression, immunodeficiency disorders, dysfunctions of homeostasis between the hormonal, circulatory, metabolic and nervous systems,
threatened neonatal infection, neoplastic diseases, viral diseases, bacterial diseases, therapy-resistant infectious factor diseases, viral and bacterial mixed infections, chronic manifestations of infectious processes, liver disorders of various etiologies, chronic skin disorders, herpetic diseases, chronic hepatitides, influenzal infections, endotoxin damage.
35. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 34, for treatment by local administration via the skin or mucous membranes of patient.
36. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 35 for local or parenteral administration.
37. The attenuated myxomavirus or the component thereof, the myxomavirus and/or the pharmaceutical composition according to any one of claims 17 to 36 for administration in the form of buccal and suckable tablets.
38. An attenuated myxomavirus strain deposited at the European Collection of Cell Cultures (ECACC) with the deposit number 03121801.


The invention relates to monoparaimmunity inducers that are based on paraimmunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show the general symptoms of the disease. The invention also relates to a method for producing the inventive inducers and to their use as drugs for the regulatory optimization of the paraimmunizing activities for use in the prophylaxis and therapy of various human and animal dysfunctions.

Documents:

01482-kolnp-2006 abstract.pdf

01482-kolnp-2006 claims.pdf

01482-kolnp-2006 correspondence others.pdf

01482-kolnp-2006 correspondence-1.2.pdf

01482-kolnp-2006 description(complete).pdf

01482-kolnp-2006 form-1.pdf

01482-kolnp-2006 form-18.pdf

01482-kolnp-2006 form-3.pdf

01482-kolnp-2006 form-5.pdf

01482-kolnp-2006 international publication.pdf

01482-kolnp-2006 international search authority report.pdf

01482-kolnp-2006 pct form.pdf

01482-kolnp-2006 priority document.pdf

01482-kolnp-2006-assignment.pdf

01482-kolnp-2006-correspondence others-1.1.pdf

01482-kolnp-2006-form-13.pdf

01482-kolnp-2006-form-3-1.1.pdf

01482-kolnp-2006-priority document-1.1.pdf

1482-KOLNP-2006-(02-02-2012)-CORRESPONDENCE.pdf

1482-KOLNP-2006-(02-02-2012)-FORM-27.pdf

1482-KOLNP-2006-(02-02-2012)-PA.pdf

1482-KOLNP-2006-ABSTRACT.pdf

1482-KOLNP-2006-AMANDED CLAIMS.pdf

1482-KOLNP-2006-AMANDED PAGES OF SPECIFICATION.pdf

1482-kolnp-2006-assignment.pdf

1482-KOLNP-2006-CORRESPONDENCE 1.2.pdf

1482-KOLNP-2006-CORRESPONDENCE-1.3.pdf

1482-KOLNP-2006-CORRESPONDENCE.pdf

1482-KOLNP-2006-DESCRIPTION (COMPLETE).pdf

1482-KOLNP-2006-ENGLISH TRANSLATION.pdf

1482-kolnp-2006-examination report.pdf

1482-kolnp-2006-examination report1.1.pdf

1482-kolnp-2006-form 1-1.1.pdf

1482-KOLNP-2006-FORM 1.pdf

1482-kolnp-2006-form 13-1.1.pdf

1482-KOLNP-2006-FORM 13.pdf

1482-kolnp-2006-form 18.pdf

1482-KOLNP-2006-FORM 2.pdf

1482-KOLNP-2006-FORM 27.pdf

1482-KOLNP-2006-FORM 3 1.2.pdf

1482-KOLNP-2006-FORM 3-1.1.pdf

1482-kolnp-2006-form 3-1.3.pdf

1482-KOLNP-2006-FORM 3.pdf

1482-kolnp-2006-form 5.pdf

1482-kolnp-2006-gpa-1.1.pdf

1482-KOLNP-2006-GPA.pdf

1482-kolnp-2006-granted-abstract.pdf

1482-kolnp-2006-granted-claims.pdf

1482-kolnp-2006-granted-description (complete).pdf

1482-kolnp-2006-granted-form 1.pdf

1482-kolnp-2006-granted-form 2.pdf

1482-kolnp-2006-granted-letter patent.pdf

1482-kolnp-2006-granted-specification.pdf

1482-KOLNP-2006-INTERNATIONAL SEARCH REPORT 1.1.pdf

1482-KOLNP-2006-IPRB.pdf

1482-KOLNP-2006-OTHERS DOCUMENTS 1.1.pdf

1482-KOLNP-2006-OTHERS-1.2.pdf

1482-kolnp-2006-others-1.3.pdf

1482-KOLNP-2006-OTHERS.pdf

1482-KOLNP-2006-PA-1.1.pdf

1482-KOLNP-2006-PA-1.2.pdf

1482-KOLNP-2006-PA.pdf

1482-KOLNP-2006-PETITION UNDER RULE 137.pdf

1482-KOLNP-2006-REPLY TO EXAMINATION REPORT-1.1.pdf

1482-kolnp-2006-reply to examination report-1.2.pdf

1482-KOLNP-2006-REPLY TO EXAMINATION REPORT.pdf


Patent Number 244356
Indian Patent Application Number 1482/KOLNP/2006
PG Journal Number 50/2010
Publication Date 10-Dec-2010
Grant Date 02-Dec-2010
Date of Filing 31-May-2006
Name of Patentee BAVARIAN NORDIC A/S
Applicant Address BOGESKOVVEJ 9, DK-3490 KVISTGAARD
Inventors:
# Inventor's Name Inventor's Address
1 MAYR, ANTON WEILHEIMER STRASSE 1, 82319 STRANBERG
2 MAYR, BARBARA WEILHEIMER STRASSE 1, 82319 STARNBERG
PCT International Classification Number A61K39/275; A61K35/76; C12N7/06
PCT International Application Number PCT/EP2005/000582
PCT International Filing date 2005-01-21
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 10 2004 003 572.5 2004-10-23 Germany